Opioid Induced Constipation News and Research

RSS
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Naloxegol holds hope for opioid-induced constipation

Naloxegol holds hope for opioid-induced constipation

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

Opioids already in the body can enhance malignant tendencies of human cancer cells

Opioids already in the body can enhance malignant tendencies of human cancer cells

Sucampo receives supplement approval from FDA for AMITIZA

Sucampo receives supplement approval from FDA for AMITIZA

TD-1211 may relieve opioid-induced constipation

TD-1211 may relieve opioid-induced constipation

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Cubist second quarter total net revenues increase 30% to $230.6M

Cubist second quarter total net revenues increase 30% to $230.6M

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC